Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

@article{Amado2008WildtypeKI,
  title={Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.},
  author={Rafael G. Amado and M Wolf and Marc Peeters and Eric Van Cutsem and Salvatore Siena and Daniel J. Freeman and Todd Juan and Robert S. Sikorski and Sid Suggs and Robert R Radinsky and Scott Patterson and David D. Chang},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 10},
  pages={1626-34}
}
PURPOSE Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials. PATIENTS AND METHODS KRAS mutations were detected using polymerase chain reaction on DNA from tumor… CONTINUE READING
Highly Influential
This paper has highly influenced 72 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS